Neumora Therapeutics is trading at $0.49, up 6.06% in pre-market, alongside broad biotech-sector strength. - XBI was up 3.64% pre-market; no new company-specific announcement explaining the October 21 rise surfaced in the search. - Neumora’s Phase 3 navacaprant failures and decision to discontinue development were previously reported, not a fresh catalyst. - No trading-volume details were available.